BACKGROUND: A quadrivalent meningococcal diphtheria conjugate vaccine (MCV-4) has been developed to provide T-cell dependent immune responses against 4 major disease-causing serogroups (A, C, Y, W-135). METHODS: In a comparative, randomized, modified double blind, controlled study in healthy 2- to 10-year-old U.S. children, safety and immunogenicity profiles of MCV-4 (n = 696) were compared with those of a licensed quadrivalent polysaccharide vaccine, Menomune A/C/Y/W-135 (PSV-4, n = 702). Vaccine-related adverse reactions were assessed for 28-day and 6-month follow-up periods. Serum bactericidal activity (SBA) was assayed in prevaccination, day 28 and 6-month postvaccination sera samples. RESULTS: Both vaccines were well-tolerated, with no vaccine-related serious adverse events and similar rates of mostly mild local and systemic reactions. Functional antibody (SBA) seroconversion percentages were significantly higher for all 4 serogroups in the MCV-4 group. The SBA geometric mean titers against serogroups A, C, Y and W-135 with MCV-4 were 1700, 354, 637 and 750, respectively, compared with PSV-4 (893, 231, 408 and 426) 28 days postvaccination (P < 0.001 for all comparisons). This significant difference persisted through 6 months. CONCLUSIONS: In 2- to 10-year-old children MCV-4 had a safety profile similar to that of PSV-4 and elicited significantly higher and more persistent serum bactericidal antibody responses against meningococcal serogroups A, C, Y and W-135 than did the licensed polysaccharide vaccine.
RCT Entities:
BACKGROUND: A quadrivalent meningococcal diphtheria conjugate vaccine (MCV-4) has been developed to provide T-cell dependent immune responses against 4 major disease-causing serogroups (A, C, Y, W-135). METHODS: In a comparative, randomized, modified double blind, controlled study in healthy 2- to 10-year-old U.S. children, safety and immunogenicity profiles of MCV-4 (n = 696) were compared with those of a licensed quadrivalent polysaccharide vaccine, Menomune A/C/Y/W-135 (PSV-4, n = 702). Vaccine-related adverse reactions were assessed for 28-day and 6-month follow-up periods. Serum bactericidal activity (SBA) was assayed in prevaccination, day 28 and 6-month postvaccination sera samples. RESULTS: Both vaccines were well-tolerated, with no vaccine-related serious adverse events and similar rates of mostly mild local and systemic reactions. Functional antibody (SBA) seroconversion percentages were significantly higher for all 4 serogroups in the MCV-4 group. The SBA geometric mean titers against serogroups A, C, Y and W-135 with MCV-4 were 1700, 354, 637 and 750, respectively, compared with PSV-4 (893, 231, 408 and 426) 28 days postvaccination (P < 0.001 for all comparisons). This significant difference persisted through 6 months. CONCLUSIONS: In 2- to 10-year-old children MCV-4 had a safety profile similar to that of PSV-4 and elicited significantly higher and more persistent serum bactericidal antibody responses against meningococcal serogroups A, C, Y and W-135 than did the licensed polysaccharide vaccine.
Authors: Ana Cristina C Frota; Lucimar G Milagres; Lee H Harrison; Bianca Ferreira; Daniela Menna Barreto; Gisele S Pereira; Aline C Cruz; Wania Pereira-Manfro; Ricardo Hugo de Oliveira; Thalita F Abreu; Cristina B Hofer Journal: Pediatr Infect Dis J Date: 2015-05 Impact factor: 2.129
Authors: Helen Findlow; Jo Southern; Lesley Mabey; Paul Balmer; Robert S Heyderman; Cressida Auckland; Rhonwen Morris; Elizabeth Miller; Ray Borrow Journal: Clin Vaccine Immunol Date: 2006-04
Authors: Peter T Beernink; Jo Anne Welsch; Lee H Harrison; Arunas Leipus; Sheldon L Kaplan; Dan M Granoff Journal: J Infect Dis Date: 2007-04-05 Impact factor: 5.226
Authors: Raymond S W Tsang; Averil M Henderson; Marissa L Cameron; Shaun D Tyler; Shari Tyson; Dennis K S Law; Jan Stoltz; Wendell D Zollinger Journal: J Clin Microbiol Date: 2007-04-18 Impact factor: 5.948
Authors: George K Siberry; Meredith G Warshaw; Paige L Williams; Stephen A Spector; Michael D Decker; Patrick Jean-Philippe; Ram Yogev; Barbara E Heckman; Adam Manzella; Jhoanna Roa; Sharon Nachman; Jorge Lujan-Zilbermann Journal: Pediatr Infect Dis J Date: 2012-01 Impact factor: 2.129
Authors: Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil Journal: MMWR Recomm Rep Date: 2020-09-25